Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer (Q86958692)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Phase II study of weekly PM00104 (ZALYPSIS(®)) in patients with pretreated advanced/metastatic endometrial or cervical cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

main subject

cervix uterine cancer

1 reference

Lainie P Martin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Carolyn Krasner

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Teresa Rutledge

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Manuel Luque Ibañes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Eva M Fernández-García

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Carmen Kahatt

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Mariano Siguero Gómez

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Scott McMeekin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

15 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

627

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771800%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12032-013-0627-3

3 March 2020

exact match

0 references

cites work

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

12 December 2020

Optimal two-stage designs for phase II clinical trials

1 reference

12 December 2020

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

12 December 2020

Renieramycin J, a highly cytotoxic tetrahydroisoquinoline alkaloid, from a marine sponge Neopetrosia sp..

1 reference

12 December 2020

Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors

1 reference

12 December 2020

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

1 reference

12 December 2020